Physician profile

Michael E Shinn

Family Medicine · Kansas City, MO

NPI 1851398861

$3,006.89

in general payments reported to CMS, 2019-2025

31 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $536.24 2019-2021
Novo Nordisk INC $368.34 2019-2021
Amarin Pharma, INC. $356.75 2019-2021
Amgen INC. $312.96 2019-2021
Pfizer INC. $293.89 2019-2020
Abbvie INC. $230.21 2019-2021
Janssen Pharmaceuticals, INC $125.37 2019-2020
Astellas Pharma US INC $86.20 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $79.96 2019-2021
Lilly USA, LLC $65.67 2019-2021
Glaxosmithkline, LLC. $63.18 2019
Novartis Pharmaceuticals Corporation $56.52 2019-2021
E.R. Squibb & Sons, L.L.C. $51.26 2020-2021
Merck Sharp & Dohme LLC $49.38 2019-2021
Allergan, INC. $42.04 2019
Show all 31 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael E Shinn

$3,006.89

in general payments reported 2019-2025

Years
2019-2021
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/128750/michael-e-shinn

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.